AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00654732
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00654732
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00654732
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01772940
Drug: nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
Trial: NCT01772940
Drug: ritonavir-boosted Lopinavir
RxNorm normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
Trial: NCT01772940
Drug: Tenofovir/emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
Trial: NCT01772940
Drug: Zidovudine/lamivudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
Trial: NCT00305396
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03880357
Drug: Betamethasone Scalp Suspension 0.064%;0.0005%
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Trial: NCT01090752
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Trial: NCT00946712
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03577457
Drug: oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal administration of oxytocin (24 IU)
Trial: NCT00814255
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
Trial: NCT00814255
Drug: Lisinopril, losartan, and atorvastatin
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
Trial: NCT01090752
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Trial: NCT00814255
Drug: galactose
RxNorm normalized name: Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
Trial: NCT03346837
Drug: BMS-986205
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986205
Trial: NCT03346837
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT03346837
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01734902
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar coated tablets for oral administration
Trial: NCT01734902
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drops for oral administration
Trial: NCT00946712
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03583138
Drug: buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To provide buprenorphine for 12 months for those who are interested in receiving it.
Trial: NCT04430998
Drug: Zinc L-Carnosine
RxNorm normalized name: L-Carnosine
DrugBank: Polaprezinc (DB09221)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
Trial: NCT04430998
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
Trial: NCT00758563
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice daily
Trial: NCT00758563
Drug: Triclosan/Fluoride
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice daily
Trial: NCT01463033
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 55 mg/kg/day given in 2 divided doses 12 hours apart
Trial: NCT03485157
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 1 mL 0.9% Sodium Chloride, USP
Trial: NCT00399087
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine oral administration
Trial: NCT00399087
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV administration
Trial: NCT00399087
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01968980
Drug: Bococizumab (PF-04950615;RN316)
RxNorm normalized name: Brolucizumab
DrugBank: Bococizumab (DB12456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg every 2 weeks, subcutaneous injection, 12 months
Trial: NCT00575666
Drug: Insulin or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intranasal, 40IU, 4 times daily
Trial: NCT01435161
Drug: Nifedipine,
RxNorm normalized name: nifedipine, micronized
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine 30-60mg/day
Trial: NCT01435161
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 80-160mg/day
Trial: NCT01923376
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
Trial: NCT01923376
Drug: Polyethylene Glycol 3350
RxNorm normalized name: Polyethylene Glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
Trial: NCT00101348
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT05586750
Drug: Atorvastatin 40 Mg Oral Tablet
RxNorm normalized name: atorvastatin 40 mg oral tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
Trial: NCT01468155
Drug: dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 days pre ablation and 90 days post ablation
Trial: NCT01409408
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg of aliskiren daily for 8 weeks.
Trial: NCT01409408
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg daily for 8 weeks.
Trial: NCT00811837
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT00646230
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02020161
Drug: Atra
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02020161
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00587119
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Budesonide, 3 mg three times daily, will be given for 1 year.
Trial: NCT01331590
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01331590
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01331590
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01331590
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01331590
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00656370
Drug: recombinant human hyaluronidase
RxNorm normalized name: Recombinant human hyaluronidase
DrugBank: Hyaluronidase (human recombinant) (DB06205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 Units in 1mL
Trial: NCT00000621
Drug: all trans retinoic acid
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000621
Drug: 13 cis retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01375387
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg oral tablet, single dose
Trial: NCT01375387
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide 2 X 100 mg tablet
Trial: NCT01375387
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide 4 X 100mg tablet
Trial: NCT02740985
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
Trial: NCT02740985
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets.
Trial: NCT02740985
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules.
Trial: NCT02740985
Drug: Oleclumab
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
Trial: NCT02740985
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice.
Trial: NCT01722669
Drug: isoquercetin or quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose PK/PD study
Trial: NCT02128022
Drug: GLP-1 (7-36) amide
RxNorm normalized name: GLP-1 (7-36) amide
DrugBank: GLP-1 (7-36) amide (DB19258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
Trial: NCT02128022
Drug: Glibenclamide
RxNorm normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Glibenclamide 5mg
Trial: NCT04118764
Drug: Definity
RxNorm normalized name: Definity
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
Trial: NCT04736355
Drug: DAOIB
RxNorm normalized name: Dapagliflozin and Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral, for 24 weeks
Trial: NCT00892996
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metoclopramide 10 mg and dexamethasone 5 mg intravenous
Trial: NCT00892996
Drug: dexamethasone 5 mg
RxNorm normalized name: dexamethasone 5 MG/ML
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ondansetron 8 mg and dexamethasone 5 mg IV
Trial: NCT00853723
Drug: Parathyroid hormone related protein (1-36)
RxNorm normalized name: Parathyroid hormone related protein (1-36)
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
Trial: NCT00853723
Drug: Parathyroid hormone related protein(1-36)
RxNorm normalized name: Parathyroid hormone related protein(1-36)
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
Trial: NCT03713801
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
Trial: NCT00060125
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01221116
Drug: levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levosimendan 0.1 microgram/kg/min) for 24 hours
Trial: NCT00867607
Drug: MRX-6
RxNorm normalized name: MRx-4DP0004
DrugBank: MRx-4DP0004 (DB15751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d treatment for 21 days
Trial: NCT01282541
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
Trial: NCT01282541
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
Trial: NCT01216488
Drug: Xylocaine
RxNorm normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 ml or 25 ml of Xylocaine injection
Trial: NCT00273884
Drug: Amonafide L-Malate
RxNorm normalized name: samidorphan L-malate
DrugBank: Amonafide (DB05022)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00273884
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00586157
Drug: Methylphenidate Transdermal System
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
Trial: NCT01318681
Drug: cetirizine 10 mg
RxNorm normalized name: cetirizine 10 MG
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cetirizine 10 mg over encapsulated
Trial: NCT01318681
Drug: fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: nasal spray 25ug per dose
Trial: NCT02573064
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02573064
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03801525
Drug: Ublituximab
RxNorm normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion
Trial: NCT03801525
Drug: Umbralisib
RxNorm normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form
Trial: NCT03801525
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form
Trial: NCT02589821
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Trial: NCT03663582
Drug: Teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
Trial: NCT03606577
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
Trial: NCT03606577
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
Trial: NCT03606577
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
Trial: NCT03606577
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
Trial: NCT00853723
Drug: Parathyroid hormone (1-34)
RxNorm normalized name: Transcon parathyroid hormone (1-34)
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
Trial: NCT01053000
Drug: Tazorac
RxNorm normalized name: Tazorac
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
Trial: NCT01335607
Drug: Samatasvir tablet
RxNorm normalized name: Samatasvir
DrugBank: Samatasvir (DB12660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)